Management of seasonal influenza with the neuraminidase inhibitor oseltamivir;Bedeutung des neuraminidase-inhibitors oseltamivir in der therapie der saisonalen influenza

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 23, 2008, Pages 1259-1264

  Ruf, Bernhard R ^a,e   Sandow, P ^b   Lehmann, P ^c   Del Piero, L ^d   Skopnik, H ^e  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Allgemeinärztliche Praxis   (Germany)

^c Kinderärztliche Praxis ^*

^d Klinikum Worms   (Germany)

^e Klinikum St Georg   (Germany)

Author keywords

Epidemic; Influenza; Neuraminidase inhibitors; Oseltamivir; Secondary complications

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

DRUG EFFICACY; DRUG INDICATION; HUMAN; INFLUENZA; REVIEW; AGE; ANTIVIRAL RESISTANCE; DRUG ANTAGONISM; DRUG EFFECT; MORTALITY; RISK FACTOR; SEASON; TIME; TREATMENT OUTCOME; VIRUS SHEDDING;

AGE FACTORS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; RISK FACTORS; SEASONS; TIME FACTORS; TREATMENT OUTCOME; VIRUS SHEDDING;

EID: 44449115665     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1077250     Document Type: Review

References (35)

1. Aoki FY, MacLeod MD, Paggiaro P et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51: 123-129
2. Arbeitsgemeinschaft Influenza. Abschlussberichte der Saisons 2002-2007, http://influenza.rki.de/index.html?c=Saisonbericht
3. Barr CE, Schulman K, Iacuzio D et al. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin 2007; 23 (3): 523-531
4. Bhat N, Wright JG, Broder KR et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005; 353: 2559-2567
5. Falsey AR, Murata Y, Wlash EE et al. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med 2007; 167 (4): 354-360
6. Goodwin K, Viboud C, Simonsen S. Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine 2006; 24: 1159-1169
7. Hayden FG, Atmar RL, Schilling M et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341 (18): 1336-1343
8. Hayden FG, Treanor JJ, Fritz RS et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240-1246
9. Hayden FG, Robson R, Jennings L et al. Efficacy of oral oseltamivir in experimental human influenza B virus infection (abstract). Clin Infect Dis 1999; 282: 1240-1246
10. Holm MV, Blank PR, Szucs T. Trends in influenza vaccination coverage rates in Germany over five seasons from 2001 to 2006. BMC Infect Dis 2007; 7: 144-
11. Jefferson T. Influenza vaccination: policy versus evidence. BMJ 2006; 333 (7574): 912-915
12. Jefferson TO, Rivetti D, DiPietrantonj C et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007(2CD001269
13. Jefferson TO, Rivetti D, Rivetti A et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366 (9492): 1165-74Review. Erratum in: Lancet 2006 Mar 25; 367(9515): 986
14. Kaiser L, Wat C, Mills T et al. Impact of oseltamivir treatment on influenza-related respiratory tract complications and hospitalisations. Arch Intern Med 2002; 163: 1667-1672
15. Leitmeyer K, Buchholz U, Kramer M et al. Influenza vaccination in German health care workers: effects and findings after two rounds of a nationwide awareness campaign. Vaccine 2006; 24: 70003-70008
16. Lin JT, Yu XZ, Cui DJ et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Curr Med Res Opin 2006; 22 (1): 75-82
17. Machado CM, Boas LS, Mendes AV et al. Use of Oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant 2004; 34(2): 111-114
18. McGeer A, Green K, Plevneshi A et al, for the Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring Hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45 (12): 1568-1575
19. Meier CR, Napalkow PN, Wegmüller Y et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associtaed with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19: 834-842
20. Monto AS, McKimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50 (7): 2395-2402
21. Nichols WG, Guthrie KA, Corey L et al. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39 (9): 1300-1306
22. Nicholson KG, Aoki FY, Vrooman PS et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845-1850
23. Nordstrom BL, Sung I, Suter P et al. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005; 21: 761-768
24. Pafriarca PA, Weber JA, Meissner MK et al. Use of influenza vaccine in nursing homes. J Am Geriatr Soc 1985; 33 (7): 463-466
25. Patriarca PA, Weber JA, Parker RA et al. Risk factors for outbreaks of influenza in nursing homes. A case-control study. Am J Epidemiol 1986; 124 (1): 114-119
26. Peters PHJr, Gravenstein S, Norwood P et al. Long-term use of oseltamivir in the prophylaxis of influenza in household contacts. A randomized controlled trial. Journal of the American Geriatric Society 2001; 49: 1025-1031
27. Shugarman LR, Hales C, Setodji CM et al. The influence of staff and resident immunization rates on influenza-like illness outbreaks in nursing homes. J Am Med Dir Assoc 2006; 7 (9): 562-567
28. Simonsen L, Taylor RJ, Viboud C et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7: 658-666
29. Stevenson CG, McArthur MA, Naus M et al. Prevention of influenza and pneumococcal pneumonia in Canadian long-term care facilities: how are we doing? CMAJ 2001; 164 (10): 1413-1419
30. Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292 (11): 1333-1340
31. Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283 (8): 1016-1024
32. Uphoff H, Groniewicz I, Soriano M et al. A surveillance system for the real-time reporting of influenza activity. Dis Manage Health Outcomes 2004; 12 (3): 197-206
33. Ward P, Small I, Smith J et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55 Suppl 1: i5-i21
34. Welliver R, Monto AS, Carewicz O et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285 (6): 748-754
35. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20 (2): 127-33Erratum in: Pediatr Infect Dis J 2001; 20(4): 421